Luca Malorni, Director of the Translational Research Unit at AUSL Toscana Centre at Hospital of Prato, shared on X:
“Here’s our editorial in Annals of Oncology discussing the results of the SERENA-1 trial where we share some open questions, including the issue of patients selection for these new endocrine agents.”
Source: Luca Malorni/X
The new oral SERDs in endocrine-resistant breast cancer: who will benefit the most?
Authors: I. Migliaccio, L. Biganzoli, and L. Malorni.
